FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BE	ENEFICIAL OWNERSHIP
----------------------------	---------------------

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Newton Charles W.				2. Issuer Name and Ticker or Trading Symbol Coherus BioSciences, Inc. [CHRS]							(Ch	elationship of eck all applic	cable) or	g Pers	10% Ov	vner		
(Last) (First) (Middle) COHERUS BIOSCIENCES, INC. 333 TWIN DOLPHIN DRIVE, SUITE 600				3. Date of Earliest Transaction (Month/Day/Year) 05/04/2022										Officer (give title below)		Other (s below)	specify	
(Street) REDWO CITY (City)	OOD C	A	94065 (Zip)		4. lf	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	X Form f	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date,			Code (Ins	on Disp tr. 5)	Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) Amount (A) or (D)			5. Amour Securitie Beneficia Owned F Reported Transact (Instr. 3 a	s ally ollowing I ion(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Co	ode	v	(A)	(D)	Date Exercisable	Expirat Date		Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$9.72	05/04/2022			A		54,000		(1)	05/04/2	2032	Common Stock	54,000	\$0	54,000)	D	

Explanation of Responses:

1. The underlying shares subject to the option vest and become exercisable as to 1/36th of the total number of shares subject to the option in successive, equal monthly installments measured from May 4, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

/s/ McDavid Stilwell, as

Attorney-in-Fact for Charles 05/06/2022

Newton

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.